Brown, Kimberley Patterson-Browning, Brooke Liu, Chris Patel, Meera Stewart, Lisa Nettles, Richard E
Published in
Reviews on recent clinical trials
An aging HIV-1-infected population warrants examination of the acceptability of individual antiretroviral regimens. In a previous study of ritonavir-boosted darunavir (ARTEMIS), similar safety/efficacy profiles were observed in younger (≤45 years) and older (>45 years) HIV-1-infected subjects. To evaluate safety and efficacy outcomes in HIV-1-infec...
Girard, P M Antinori, A Arribas, J R Ripamonti, D Bicer, C Netzle-Sveine, B Hadacek, B Moecklinghoff, C
Published in
HIV medicine
In this study, in patients with HIV-1 RNA
Pernas, Berta Grandal, Marta Tabernilla, Andrés Cid, Purificación Pértega, Sonia Castro-Iglesias, Ángeles Mena, Álvaro Margusino, Luis Pedreira, José D Poveda, Eva
...
Published in
Journal of medical virology
The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period 2007-2015). The 43.2% had a CD4 nadir ≤100 cells/mm3 , 64.1% were treatment-experienced, and 36.5% had failed to >3 lines of antiretroviral ther...
Goizman, M. S. Zotova, O. A. Kamalova, A. A. Popova, A. O. Shobolov, D. L. Korlyukov, A. A. Suponitskii, K. Yu. Shimanovskii, N. L. Zaitsev, S. A. Degterev, E. V.
...
Published in
Pharmaceutical Chemistry Journal
It is shown that prolongation of patent protection for the antiviral drug darunavir by patenting it again as darunavir ethanolate is illegal. The claims of the successor patent “Pseudopolymorphic forms of a HIV protease inhibitor,” WO 2003106461 A2, are analyzed and shown to be invalid from both scientific and ethical viewpoints. It is established ...
Larson, Kajal B Cressey, Tim R Yogev, Ram Wiznia, Andrew Hazra, Rohan Jean-Philippe, Patrick Graham, Bobbie Gonzalez, Amy Britto, Paula Carey, Vincent J
...
Published in
Journal of the Pediatric Infectious Diseases Society
The results suggest that DRV/r QD with ETR 400 mg QD or 200 mg BID is appropriate and support further evaluation of the safety and efficacy of the once-daily regimen in older children, adolescents, and young adults.
Nguyen, Duong Nhat Palangetic, Ljiljana Clasen, Christian Van den Mooter, Guy
Published in
The Journal of pharmacy and pharmacology
This study showed the potential of coaxial electrospraying for encapsulating solid dispersions within core-shell structured nanoparticles.
Ahmed, Nadia Okoli, Chinyere Ainsworth, Jonathan
Published in
International journal of STD & AIDS
Novel two-drug combinations including a protease inhibitor are an attractive nucleoside reverse transcriptase inhibitor sparing option for some patients, particularly as a switch strategy. We have used the two-drug combination of maraviroc and darunavir/ritonavir once a day as a switch strategy in patients with stable low or undetectable plasma HIV...
Calza, Leonardo Danese, Ilaria Magistrelli, Eleonora Colangeli, Vincenzo Manfredi, Roberto Bon, Isabella Re, Maria Carla Conti, Matteo Viale, Pierluigi
Published in
HIV clinical trials
In our study, simplification to a dual therapy containing raltegravir plus darunavir/ritonavir after 48 weeks maintained viral suppression in more than 90% of patients and showed a good tolerability with a favourable effect on proteinuria, ipophosphoremia, and lipid metabolism.
Crutchley, Rustin D Guduru, Rakesh C Cheng, Amy M
Published in
HIV/AIDS (Auckland, N.Z.)
Atazanavir/cobicistat (ATV/c) and darunavir/cobicistat (DRV/c) are newly approved once daily fixed-dose protease inhibitor combinations for the treatment of HIV-1 infection. Studies in healthy volunteers have established bioequivalence between cobicistat and ritonavir as pharmacoenhancers of both atazanavir (ATV) and darunavir (DRV). In addition, t...
Taramasso, Lucia Dentone, Chiara Alessandrini, Anna Bruzzone, Bianca Icardi, Giancarlo Garraffo, Rodolphe De Macina, Ilaria Viscoli, Claudio Di Biagio, Antonio
Published in
International journal of STD & AIDS
In the context of HIV-infected patients with several past antiretroviral therapies and multiple failures, it is possible to be faced with viruses resistant to all drug classes. We report on two HIV-1 infected patients in which the historical genotype showed mutations against all the major drug classes and in which viral suppression has been obtaine...
